Scarica l'app Stockscreener
14.35
0.14%
-0.02
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché FOLD Giù?
Forum
Previsione
Amicus Therapeutics Inc Borsa (FOLD) Ultime notizie
Jefferies Downgrades Amicus Therapeutics, Inc. (FOLD) to Buy And Lowers Price Target Amid Takeover Developments - MSN
How The Amicus Therapeutics (FOLD) Story Is Shifting Inside BioMarin’s Rare Disease Portfolio - Yahoo Finance
Amicus Therapeutics Buyout Advances As Valuation Gap Draws Investor Focus - Yahoo Finance
Bradley Campbell Sells 22,500 Shares of Amicus Therapeutics (NASDAQ:FOLD) Stock - MarketBeat
Insider Sell: Bradley Campbell Sells 22,500 Shares of Amicus The - GuruFocus
FOLD SEC FilingsAmicus Therapeut 10-K, 10-Q, 8-K Forms - Stock Titan
FDA’s rare disease toolbox not fully used - BioWorld MedTech
JPMorgan Chase & Co. Has $16.68 Million Stock Position in Amicus Therapeutics, Inc. $FOLD - MarketBeat
Is It Too Late To Consider Amicus Therapeutics (FOLD) After The Proposed BioMarin Deal Price? - simplywall.st
Amicus Therapeutics shareholders approve acquisition by BioMarin Pharmaceutical - Investing.com
Amicus Stockholders Approve BioMarin Acquisition at Special Meeting - TipRanks
Shareholders back Amicus (NASDAQ: FOLD) sale to BioMarin Pharmaceutical - Stock Titan
Amicus Therapeutics, Inc. (FOLD) Stock Analysis: Navigating the Biotech Sector with a 23.7% Revenue Growth - DirectorsTalk Interviews
Bradley Campbell sells 75,000 FOLD shares under 10b5-1 plan (FOLD) - Stock Titan
Vanguard Group Inc. Buys 126,441 Shares of Amicus Therapeutics, Inc. $FOLD - MarketBeat
FOLD Stock Price, Quote & Chart | AMICUS THERAPEUTICS INC (NASDAQ:FOLD) - ChartMill
William Blair Investment Management LLC Buys 1,107,083 Shares of Amicus Therapeutics, Inc. $FOLD - MarketBeat
Fox Run Management L.L.C. Takes $553,000 Position in Amicus Therapeutics, Inc. $FOLD - MarketBeat
Primecap Management Co. CA Sells 128,200 Shares of Amicus Therapeutics, Inc. $FOLD - MarketBeat
FOLD Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Amicus Therapeutics Experiences Revision in Stock Score Amid Mixed Financial Performance - Markets Mojo
BIOMARIN PHARMACEUTICAL INC SEC 10-K Report - TradingView
BioMarin Deal Reshapes Amicus Therapeutics Outlook For Growth And Portfolio - simplywall.st
Amicus Therapeutics, Inc. (FOLD) Stock Analysis: Navigating Growth in Rare Diseases with Strong Revenue Momentum - DirectorsTalk Interviews
BioMarin Amicus Deal Shifts Rare Disease Portfolio And Valuation Focus - Yahoo Finance
Precision Trading with Amicus Therapeutics Inc. (FOLD) Risk Zones - Stock Traders Daily
BioMarin Reports Fourth Quarter and Full-year 2025 Financial and Operating Results - The AI Journal
Amicus' Q4 Earnings Miss, Higher Product Sales Drive Y/Y Revenues - Finviz
Amicus Therapeutics: Q4 Earnings Snapshot - kare11.com
Amicus Therapeutics Q4 Highlights: Revenue Growth Amid Losses - Intellectia AI
Amicus Therapeutics: Fourth Quarter Financial Results Overview - Bitget
Amicus Therapeutics Q4 Profit Print Tests Bullish Profitability Narratives - simplywall.st
Will Amicus Therapeutics Inc. benefit from sector rotationEarnings Overview Report & Daily Entry Point Alerts - mfd.ru
Amicus Therapeutics Announces Full-Year 2025 Financial Results and Corporate Updates - The Manila Times
Decoding Amicus Therapeutics Inc (FOLD): A Strategic SWOT Insigh - GuruFocus
Amicus Therapeutics (NASDAQ:FOLD) Announces Quarterly Earnings Results - MarketBeat
Amicus Therapeutics (FOLD) Beats Q4 Revenue Expectations - GuruFocus
AMICUS THERAPEUTICS, INC. SEC 10-K Report - TradingView
Is Amicus Therapeutics Inc.’s ROIC above industry averageWeekly Trading Summary & Intraday High Probability Setup Alerts - mfd.ru
TD Cowen cautious on Amicus Therapeutics (FOLD) despite positive 2025 revenue projections - MSN
BioMarin’s $4.8B move on rare-disease maker Amicus after 17% sales jump - Stock Titan
Halper Sadeh LLC is Investigating Whether RAPT, CTGO, TBN, FOLD are Obtaining Fair Deals for their Shareholders - GlobeNewswire Inc.
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Given Consensus Recommendation of “Hold” by Brokerages - Defense World
TD Cowen Cautious on Amicus Therapeutics (FOLD) Despite Positive 2025 Revenue Projections - Finviz
Amicus earnings on deck as $4.8B BioMarin deal awaits vote - Investing.com India
Aug Levels: Will Amicus Therapeutics Inc benefit from geopolitical trendsWeekly Trend Report & Smart Investment Allocation Tips - baoquankhu1.vn
Principal Financial Group Inc. Has $2.08 Million Stock Holdings in Amicus Therapeutics, Inc. $FOLD - MarketBeat
Amicus Therapeutics, Inc. (FOLD) Stock Analysis: Navigating Current Valuations with Strong Revenue Growth - DirectorsTalk Interviews
BioMarin to buy rare disease drugmaker Amicus Therapeutics for $4.8B - MSN
What to Expect From These Drug/Biotech Players This Earnings Season? - TradingView
BioMarin Debt Deal And VOXZOGO Approval Recast Rare Disease Outlook - Yahoo Finance
Can Amicus Therapeutics Inc. expand its profit marginsPortfolio Gains Summary & Smart Swing Trading Techniques - mfd.ru
BioMarin Pharmaceutical, Amicus Therapeutics deal gets early termination from US FTC - MLex
Why Amicus Therapeutics Inc. stock is in analyst buy zoneJuly 2025 Final Week & Trade Opportunity Analysis - mfd.ru
0.70%
20.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):